Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or
the “Company”) today announced that it will host a Research &
Development Day (R&D Day) for analysts and accredited
institutional investors with live video webcast (details below) on
Friday, June 21, 2019 from 10:00 AM – 1:00 PM ET in New York, NY.
Yuval Cohen, Ph.D., Chief Executive Officer of
Corbus, will host the event and will be joined by Barbara White,
M.D., Chief Medical Officer & Head of Research and Sergei
Atamas, M.D., Ph.D., Executive Director of Research.
At the R&D Day, Corbus will provide an
overview and clinical update for lenabasum, including the recently
presented data from the open-label extensions of its Phase 2
studies in two rare and serious autoimmune diseases: systemic
sclerosis and dermatomyositis. The Company will also discuss its
ongoing Phase 2 studies of lenabasum for the treatment of cystic
fibrosis and systemic lupus erythematosus.
Additionally, Corbus will introduce CRB-4001, a
selective cannabinoid receptor type 1 inverse agonist designed to
target NASH/NAFLD indications. Corbus plans to commence a Phase 1
clinical study of CRB-4001 in 2019.
Lastly, the Company will present its proprietary
platform of compounds that target the endocannabinoid system.
Webcast Details
Interested participants and investors may dial
into the event using (877) 407-3978 (domestic) or (412) 902-0039
(international), or can access the live video webcast and
accompanying slide presentation on the Events page of the Investors
section of the Corbus website, www.corbuspharma.com. The webcast
replay will be archived for 90 days following the event.
About Lenabasum
Lenabasum is a rationally-designed, oral, small
molecule that selectively binds as an agonist to the cannabinoid
receptor type 2 (CB2) and has been designed to resolve
inflammation, limit fibrosis and support tissue repair. CB2 is
preferentially expressed on activated immune cells and also on
fibroblasts, muscle cells, and endothelial cells. In both animal
and human studies conducted to date, lenabasum has induced the
production of pro-resolving lipid mediators that activate
endogenous pathways which resolve inflammation and speed bacterial
clearance without immunosuppression. Data from animal models and
human clinical studies suggest that lenabasum can reduce expression
of genes and proteins involved in inflammation and fibrosis.
Lenabasum has demonstrated promising activity in animal models of
skin and lung inflammation and fibrosis in systemic sclerosis
(SSc). Lenabasum is also active in animal models of lung infection
and inflammation in cystic fibrosis and joint inflammation and
scarring in rheumatoid arthritis.
Lenabasum has demonstrated an acceptable safety
and tolerability profiles in clinical studies to date. Lenabasum
treatment was associated with improvement in multiple
physician-assessed and patient-reported efficacy outcomes in Phase
2 studies in patients with diffuse cutaneous SSc and patients with
DM with active skin involvement but not currently active muscle
involvement. Lenabasum treatment also was associated with a lower
rate of and longer time to pulmonary exacerbations in a Phase 2
cystic fibrosis study. Additional clinical studies are being
conducted to confirm these results and support applications for
regulatory approval.
About Corbus
Corbus Pharmaceuticals Holdings, Inc. is a Phase
3 clinical-stage pharmaceutical company focused on the development
and commercialization of novel therapeutics to treat inflammatory
and fibrotic diseases by leveraging its pipeline of endocannabinoid
system-targeting synthetic drug candidates. The Company's lead
product candidate, lenabasum, is a novel, synthetic, oral,
selective cannabinoid receptor type 2 (CB2) agonist designed to
resolve chronic inflammation and fibrotic processes. Lenabasum is
currently being evaluated in systemic sclerosis, cystic fibrosis,
dermatomyositis, and systemic lupus erythematosus.
Corbus is also developing a pipeline of drug
candidates from more than 600 novel compounds targeting the
endocannabinoid system. The pipeline includes CRB-4001, a 2nd
generation, peripherally-restricted, selective cannabinoid receptor
type 1 (CB1) inverse agonist. Potential indications for CRB-4001
include NASH, among others. Corbus plans to start a Phase 1 study
of CRB-4001 in 2019, intended to be followed by a National
Institutes of Health (NIH)-funded proof-of-concept Phase 2
study.
For more information, please visit
www.CorbusPharma.com and connect with the Company on Twitter,
LinkedIn, and Facebook.
Forward-Looking Statements
This press release contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934 and Private Securities Litigation Reform Act, as
amended, including those relating to the Company's product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of
forward-looking expressions, including, but not limited to,
"expect," "anticipate," "intend," "plan," "believe," "estimate,"
"potential, "predict," "project," "should," "would" and similar
expressions and the negatives of those terms. These statements
relate to future events or our financial performance and involve
known and unknown risks, uncertainties, and other factors which may
cause actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Such
factors include those set forth in the Company's filings with the
Securities and Exchange Commission. Prospective investors are
cautioned not to place undue reliance on such forward-looking
statements, which speak only as of the date of this press release.
The Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Corbus Pharmaceuticals Contacts:
Ted Jenkins, Senior Director, Investor Relations and Corporate
CommunicationsPhone: +1 (617) 415-7745Email:
ir@corbuspharma.com
Lindsey Smith, Associate Director, Investor Relations and
Corporate CommunicationsPhone: +1 (617) 415-7749Email:
mediainfo@corbuspharma.com
Jenene ThomasJenene Thomas Communications, LLCPhone: +1 (833)
475-8247Email: crbp@jtcir.com
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Corbus Pharmaceuticals (NASDAQ:CRBP)
Historical Stock Chart
From Apr 2023 to Apr 2024